Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Catecholamines receptor Adrenergic

The adrenergic receptors (or adrenoceptors) are a class of G-protein coupled receptors, which are the targets of catecholamines. Adrenergic receptors specifically bind their endogenous ligands, the catecholamines, epinephrine, and norepinephrine (also called adrenaline and noradrenaline), and are activated by these. [Pg.161]

Ephedrine, which is not a catecholamine, has weak oral activity as a bronchodilator and although it has some direct action at adrenergic receptors, its predominant mode of action is by displacing norepinephrine from storage vesicules. 2"Agonists which are in use or are under investigation are the result of quests for improved selectivity, retention of potency, oral activity, and longer duration of action. [Pg.438]

Furchgott, R. F. (1972). The classification of adrenoreceptors (adrenergic receptors) An evaluation from the standpoint of receptor theory. In Handbook of experimental pharmacology, catecholamines, Vol. 33, edited by H. Blaschko and E. Muscholl, pp. 283—335. Springer-Verlag, Berlin. [Pg.57]

The distinction between a- and P-adrenergic receptors was first proposed by Ahlquist in 1948 based on experiments with various catecholamine derivatives to produce excitatory (a) or inhibitory (P) responses in isolated smooth muscle systems. Initially, a further subdivision into presynaptic a2- and postsynaptic oq-receptors was proposed. However, this anatomical classification of a-adrenergic recqrtor subtypes was later abandoned. [Pg.43]

The original monoamine hypothesis of depression states that depressions are associated with a deficiency of catecholamines, particularly norepinephrine, at functionally important adrenergic receptor sites in the brain. Elation conversely may be associated with an excess of such amines. The hypothesis was articulated in 1966 only after the mechanism of action of the tricyclic antidepressant desipramine and of the psychostimulants... [Pg.840]

Sympathetic nerves are distributed to most vascular beds. They are most abundant in the renal, gastrointestinal, splenic, and cutaneous circulations. Recall that these tissues receive an abundant blood flow, more than is necessary simply to maintain metabolism. Therefore, when blood is needed by other parts of the body, such as working skeletal muscles, sympathetic vasoconstrictor activity reduces flow to the tissues receiving excess blood so that it may be redirected to the muscles. Interestingly, there is no sympathetic innervation to cerebral blood vessels. In fact, these vessels do not have a.j-adrenergic receptors, so they cannot be affected by circulating catecholamines. No physiological circumstance exists in which blood should be directed away from the brain. [Pg.203]

The major circulating hormones that influence vascular smooth muscle tone are the catecholamines epinephrine and norepinephrine. These hormones are released from the adrenal medulla in response to sympathetic nervous stimulation. In humans, 80% of catecholamine secretion is epinephrine and 20% is norepinephrine. Stimulation of cy-adrenergic receptors causes vasoconstriction. The selective a,-adrenergic receptor antagonist, prazosin, is effective in management of hypertension because it causes arterial and venous smooth muscle to relax. [Pg.209]

Beta-1, beta-2, and beta-3 adrenergic receptors are G-protein-coupled receptors. Beta-1 and beta-2 receptors mediate the positive inotropic, chronotropic, and dro-motropic effects of the endogenous catecholamines epinephrine and norepinephrine. The beta-3 subtype seems to play a role in regulating thermogenesis and lipid mobilization in brown and white adipose tissue. Several coding and promoter polymorphisms of these receptors have been identified. Clinical studies in asthma... [Pg.259]

The postsynaptic receptors on any given neuron receive information from transmitters released from another neuron. Typically, postsynaptic receptors are located on dendrites or cell bodies of neurons, but may also occur on axons or nerve terminals in the latter case, an axoaxonic synaptic relationship may cause increases or decreases in transmitter release. In contrast, autoreceptors are found on certain neurons and respond to transmitter molecules released from the same neuron. Autoreceptors may be widely distributed on the surface of the neuron. At the nerve terminal, they respond to transmitter molecules released into the synaptic cleft on the cell body, they may respond to transmitter molecules released by dendrites. Functionally, most autoreceptors appear to decrease further transmitter release in a kind of negative feedback loop. Autoreceptors have been identified for all the catecholamines, as well as for several other neurotransmitters. a2-adrenergic receptors are often found on noradrenergic nerve terminals of postganglionic sympathetic nerves, as well as on noradrenergic neurons in the CNS [36], and activation of these receptors decreases further norepinephrine release. Dopamine autoreceptors,... [Pg.218]

Vasopressin causes vasoconstrictive effects that, unlike adrenergic receptor agonists, are preserved during hypoxia and severe acidosis. It also causes vasodilation in the pulmonary, coronary, and selected renal vascular beds that may reduce pulmonary artery pressure and preserve cardiac and renal function. However, based on available evidence, vasopressin is not recommended as a replacement for norepinephrine or dopamine in patients with septic shock but may be considered in patients who are refractory to catecholamine vasopressors despite adequate fluid resuscitation. If used, the dose should not exceed 0.01 to 0.04 units/min. [Pg.167]

One of the few examples of decreased susceptibility among elderly is the effect of catecholamines on the heart. There is a down-regulation of beta-adrenergic receptors and a reduced response to beta-adrenergic stimulation (Turnheim 1998). This results in decreased effect of betablockers on heart rate and stroke volume. In the elderly betablockers may be less effective than other drugs against hypertension and they should not be considered appropriate for first-line therapy of uncomplicated hypertension in the elderly (Grossman and Messerli 2002). [Pg.16]

Cavalli, A., Fanelli, F., Taddei, C., De Benedetti, P.G. and Cotecchia, S. (1996) Amino acids of the alB-adrenergic receptor involved in agonist binding further differences in docking catecholamines to receptor subtypes. FEBS Letters, 399, 9-13. [Pg.187]

The inotropic effects of these agents are not mediated via direct stimulation of -adrenergic receptors or indirectly by release of catecholamines, but by selective inhibition of cardiac cAMP phosphodiesterase (PDE) type III [25,35-40]. Recently, it has been demonstrated that the imidazole core is primarily responsible for PDE isozyme specificity, whereas the dihydropyri-dazinone moiety is responsible for inhibitory potency the phenylene moiety obviously acts mainly as a spacer [26]. A five-point model for positive inotropic activity of PDE III inhibitors has been elaborated [41]. [Pg.146]

Figure 22.13 a-Adrenergic receptor control of contraction of smooth muscle. IP3 represents inositol trisphosphate. Binding of a catecholamine to an a-receptor activates a membrane-bound phospholipase which hydrolyses phosphatidyUnositol bisphosphate within the membrane to produce IP, and diacylglycerol (DAG). IP3 binds a receptor on the sarcoplasmic reticulum in smooth muscle, which activates a Ca ion channel and the cytosolic Ca ion concentration increases, which results in contraction of smooth muscle in arterioles. This results in vasoconstriction and hence decreases blood flow which can leading to an increase in blood pressure. [Pg.522]

Epinephrine, and endogenic catecholamine, is better known by its official English name adrenaline. Epinephrine is a powerful agonist of both a- and j8-adrenergic receptors. Its action is very complex and depends not only on the relative distribution of adrenergic receptors in... [Pg.146]

As drugs of mixed action, amphetamines activate adrenergic receptors and simultaneously release endogenic catecholamines (norepinephrine and dopamine) from neurons of the brain and periphery. Sympathomimetic effects on the periphery are very similar to those of ephedrine. Amphetamine elevates systolic and diastolic blood pressure and has weakly expressed, broncholytic action. These effects are more prolonged, yet less expressed, than with epinephrine. The distinctive feature of amphetamines is their psychostimulatory activity. Larger doses can cause hallucinations and mental conditions similar to paranoid schizophrenia. As a sympathomimetic, amphetamine is sometimes used for uterine inertia. Synonyms of amphetamine are phenamine and benzedrine. [Pg.158]

This group consists of j3-adrenergic receptor blockers, the antiarrhythmic activity of which is associated with inhibition of adrenergic innervation action of the circulatory adrenaline on the heart. Because all 8-adrenoblockers reduce stimulatory sympathetic nerve impulses of catecholamines on the heart, reduce transmembrane sodium ion transport, and reduce the speed of conduction of excitation, sinoatrial node and contractibility of the myocardium is reduced, and automatism of sinus nodes is suppressed and atrial and ventricular tachyarrhythmia is inhibited. [Pg.251]

Adrenergic receptors are located throughout the body on neuronal and nonneuronal cells where they mediate a diverse range of responses to the endogenous catecholamines adrenaline and noradrenaline. To date, nine... [Pg.162]

The adrenal medulla synthesizes two catecholamine hormones, adrenaline (epinephrine) and noradrenaline (norepinephrine) (Figure 1.8). The ultimate biosynthetic precursor of both is the amino acid tyrosine. Subsequent to their synthesis, these hormones are stored in intracellular vesicles, and are released via exocytosis upon stimulation of the producer cells by neurons of the sympathetic nervous system. The catecholamine hormones induce their characteristic biological effects by binding to one of two classes of receptors, the a- and )S-adrenergic receptors. These receptors respond differently (often oppositely) to the catecholamines. [Pg.21]

Deficiency of adrenal medullary catecholamines appears to give no ill effects, and replacement therapy is therefore not used, but adrenal medullary tumours, phaeochromocytomas, secrete excess catecholamines often causing hypertension with dramatic episodes of headache, palpitations, pallor, sweating and anxiety. This condition is normally treated surgically, but preoperative preparation is mandatory to avoid catastrophic effects of surges of catecholamine release. A combination of alpha- and beta-adrenergic receptor blockade is normally used, with drugs such as phenoxybenzamine or doxazosin as alpha-blockers, and propranolol as a non-selective beta-blocker. [Pg.768]

Devic E., L. Paquereau, R. Steinberg, D. Caput, and Y. Audigier (1997). Early expression of a beta 1-adrenergic receptor and catecholamines in Xenopus oocytes and embryos. FEES Lerrer 417 184-190. [Pg.260]

However, the posterior cortical areas may be aided by P and aj-adrenergic receptor stimulation and by dopaminergic stimulation, and thus stimulants may promote the attentional processing abilities of these areas. It is important to note that there has been no direct animal research on catecholamine modulation of posterior cortical function thus this idea remains speculative. [Pg.107]


See other pages where Catecholamines receptor Adrenergic is mentioned: [Pg.219]    [Pg.358]    [Pg.358]    [Pg.42]    [Pg.42]    [Pg.46]    [Pg.274]    [Pg.1206]    [Pg.208]    [Pg.212]    [Pg.177]    [Pg.37]    [Pg.48]    [Pg.797]    [Pg.101]    [Pg.188]    [Pg.251]    [Pg.130]    [Pg.188]    [Pg.220]    [Pg.221]    [Pg.225]    [Pg.150]    [Pg.161]    [Pg.173]    [Pg.181]    [Pg.506]    [Pg.153]    [Pg.694]   
See also in sourсe #XX -- [ Pg.220 ]




SEARCH



Adrenergic receptors receptor

Catecholamines

Catecholamines adrenergic

Receptors 3-adrenergic

© 2024 chempedia.info